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Abstract
Background Data on prevalence of sarcopenia and its associated parameters in hospitalized geriatric patients are hetero-
geneous due to various definitions of the disease. The aim of this study was to determine the prevalence of sarcopenia using
latest recommendations of the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and to investigate
associated parameters in patients admitted to acute geriatrics and geriatric rehabilitation.
Methods In this cross-sectional single-centre study including 305 hospitalized geriatric patients, handgrip strength (pneu-
matic hand dynamometer) and muscle quantity (body impedance analysis) were assessed. Probable sarcopenia was defined
by low handgrip strength, and the diagnosis was confirmed when both handgrip strength and muscle quantity were below
cut-off points. Furthermore, parameters of the geriatric baseline examination were analyzed for association with probable
and confirmed sarcopenia using logistic regression models.
Results Median age of the study population was 84.0 years, and 65.6% were female. The prevalence of probable sarcopenia
was 24.6% (CI 19.8–29.4%), and the prevalence of confirmed sarcopenia was 22.6% (CI 17.9–27.3%). Low calf cir-
cumference, low body mass index, cognitive impairment and an increased risk of malnutrition were found to be associated
with confirmed sarcopenia. In contrast, only cognitive impairment was positively associated with probable sarcopenia.
Conclusions Sarcopenia is highly prevalent in geriatric inpatients, and multiple parameters were found to be associated with
the disease. To reduce negative clinical outcomes, our findings support the need for routinely performed admission
examinations for prompt diagnosis of sarcopenia, and a timely start of treatment in hospitalized geriatric patients.
Introduction
Sarcopenia, defined as loss of muscle mass and function [1],
is a common condition in older individuals associated with
various comorbidities such as malnutrition and cognitive
impairment [2, 3]. It further was found to be associated with
adverse clinical outcomes such as falls and fractures,
functional decline and increased mortality [4–7].
In the last years, heterogeneous data on the prevalence of
sarcopenia have been reported due to various operational
definitions and cut-off points [8]. Recently, the European
Working Group on Sarcopenia in Older People 2 (EWG-
SOP2) published an updated evidence-based consensus
report on its definition and diagnosis. These new guidelines
focus on low muscle strength as a key characteristic of
sarcopenia, use low muscle mass to confirm the diagnosis,
and suggest poor physical performance as an indicator for
severe sarcopenia [9]. Criteria of EWGSOP2 have been used
for different patient cohorts and settings. Studies reported
prevalence rates of sarcopenia between 0.4 and 9.3% in
community-dwelling older adults [7, 10–13]. Higher rates of
prevalence have been found in other patient populations
such as octogenarian males (20.0%) [14] and in patients with
liver cirrhosis (28.2%) [15]. Nonetheless, data on the pre-
valence of sarcopenia in hospitalized geriatric patients are
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scarce [16–18]. So far, no study has investigated parameters
associated with probable and confirmed sarcopenia using the
revised diagnostic criteria of EWGSOP2.
The present study aimed to investigate the prevalence of
sarcopenia and its associated parameters in patients admit-
ted to acute geriatrics and geriatric rehabilitation, using the
recommended diagnostic criteria of EWGSOP2. Given the
prevalence rates of existing data between 18.1 and 22.8%
[16–18], we hypothesized that the prevalence of sarcopenia
is higher than 20.0% in both geriatric inpatient settings.
Furthermore, we hypothesized that parameters from the
geriatric baseline evaluation associated with probable and
confirmed sarcopenia can be validated if diagnostic criteria
of EWGSOP2 are used.
Methods
Study population
This cross-sectional study was performed at a university
department of geriatric medicine between September 10 and
October 30, 2019. A consecutive convenience sample of all
patients older than 65 years, admitted to acute geriatrics and
geriatric rehabilitation, was asked to participate. Patients
with acute sepsis, severe dehydration or volume overload,
life expectancy of <3 months according to attending phy-
sician, non-removable plasters or bandages at feet or hands
aggravating body impedance analysis (BIA), implanted
defibrillation device, and inability to follow study proce-
dures (e.g., due to delirium or language barriers) were
excluded. All participants signed an informed consent form
before any study procedure was performed. If a patient was
not capable of giving informed consent due to severe cog-
nitive impairment, the consent form was signed by a proxy
person. In addition to medical treatment, the standardized
rehabilitation program during hospitalization included
physiotherapy, occupational and nutritional therapy for a
total of 300 min/week in acute geriatric patients, and
450 min/week for patients in geriatric rehabilitation.
The study was approved by the Ethics Committee of
Northwest and Central Switzerland (registration ID
2019–01461) and was registered at ClinicalTrials.gov
(NCT04124575).
Geriatric baseline examination
For all included participants, age, sex, length of hospital
stay, comorbidities and number of drugs at hospital
admission were extracted from medical records. Body
height (cm), weight (kg), calf and mid-arm circumference
(cm) were measured using standard methods. Results of
anthropometric measures and the geriatric assessment were
dichotomized at following cut-off points: Body mass index
(BMI) <22 kg/m2 for persons ≥70 years old and <20 kg/m2
for persons <70 years old (low BMI) [19]; calf cir-
cumference <31 cm (low calf circumference) [9]; mid-arm
circumference (MAC) <26.5 cm for men and <24.5 cm for
women ≥75 years old, and <27.5 cm for men and <25.5 cm
for women <75 years old (low MAC) [20]; mini mental
state exam (MMSE) <27 points (cognitive impairment)
[21]; nutritional risk screening (NRS 2002) ≥3 points (at
risk of malnutrition) [22, 23]; timed up and go test
(TUG) ≥20 s (low physical performance) [24]. Patients who
were not able to perform the TUG at admission were scored
as mobility impaired. The functional independence measure
(FIM) score was used to assess the functional status. This
clinician-reported score ranges from 18 to 126 points with
higher scores reflecting better functionality [25].
Assessment of sarcopenia
All participants were assessed for sarcopenia within the first
6 days of admission according to the recently defined
EWGSOP2 guidelines [9]. To determine muscle strength,
handgrip strength (HGS) of the dominant hand was mea-
sured with a pneumatic hand dynamometer (Martin Vig-
orimeter®, Gebrüder Martin GmBH, Tuttlingen, Germany).
HGS was measured three times and the highest value was
used for analysis. To define low HGS, cut-off points of
<50 kPa for men and <34 kPa for women >75 years old, and
<64 kPa for men and <42 kPa for women ≤75 years old were
applied [26]. BIA was performed with a tetrapolar whole-
body BIA device (BIA 101, Akern, Florence, Italy) to
determine muscle mass and phase angle, a measurement of
cell integrity. Thereby, a low value represents a decreased
cellular integrity or even cell death, whereas a high value
represents a larger amount of intact cell membranes [27]. All
participants were assessed in supine position with extre-
mities stretched. The estimates obtained for the evaluation of
appendicular skeletal muscle mass (ASMM) derive from
proprietary manufacturer algorithms and were applied using
Bodygram Plus software, version 1.2.2.8 (Akern, Florence,
Italy). Cut-off points for low appendicular skeletal muscle
mass index (ASMI), calculated from ASMM/height2, were
<7 kg/m2 for men and <5.5 kg/m2 for women [9]. According
to EWGSOP2 guidelines, sarcopenia was defined as prob-
able when HGS was low; diagnosis was made when both
HGS and muscle quantity were low, and sarcopenia was
defined as severe by additional documentation of low phy-
sical performance (TUG ≥20 s).
Statistical analysis
The study population was characterized using frequencies
(n) and percentages (%) for categorical variables, and
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medians and 25th to 75th interquartile ranges (IQR) for
continuous data. Patient characteristics in acute geriatrics
and geriatric rehabilitation were analyzed using
Pearson–Chi-square test, Fisher’s exact test and
Mann–Whitney U test, where appropriate. For power ana-
lysis, we used the method described by Daniel et al. to
calculate the sample size for cross-sectional studies [28].
According to previous reports, we assumed a prevalence of
sarcopenia of 25% [16–18]. Using a level of confidence of
95% and a precision of 5%, the calculated minimal sample
size was n= 289 [29]. Prevalence of sarcopenia was
reported as percentage (%) and 95% confidence interval
(CI). In patients assessed for sarcopenia in acute geriatrics
as well as geriatric rehabilitation, the Cohen’s kappa coef-
ficient was calculated to test the reliability between the first
and the second assessment for sensitivity analysis [30]. A
multiple logistic regression model including the parameters
age, sex, low calf circumference, low MAC, low BMI,
cognitive impairment, low physical performance, risk of
malnutrition and functional disability was applied to assess
the association of different parameters with probable and
confirmed sarcopenia. P values <0.05 were considered to be
statistically significant. All statistical analyses were per-
formed using SPSS Statistics, Version 22 (IBM SPSS Sta-
tistics, Chicago, IL).
Results
Out of 414 patients admitted to acute geriatrics and geriatric
rehabilitation, 29 were excluded because of acute sepsis,
severe dehydration or volume overload. Thirteen patients
had a remaining life expectancy of <3 months, two patients
had an implanted defibrillation device, 12 patients refused
informed consent, and 16 patients were excluded for other
reasons, e.g., plasters or bandages at feet or hands that could
not be removed. Overall, 342 admitted patients were
assessed for sarcopenia. Out of these, we excluded the
second measurement of 37 participants, as they were
assessed twice due to their admission to acute geriatrics
prior to rehabilitation, resulting in a final study population
of 305 patients. Acute illnesses representing the main cause
of hospitalization were orthopaedic (38.0%), neurological
(28.2%), infectious (15.4%) and cardiovascular (9.2%)
diseases. In addition, 9.2% of the participants were hospi-
talized for other diseases.
Clinical characteristics of the study population
Baseline characteristics of the study population, stratified by
wards (acute geriatrics and geriatric rehabilitation) and by
gender (males and females), are presented in Table 1. The
median (interquartile range) age of the study population was
84.0 (10.0) years, and 65.6% of our study participants were
female. Patients admitted to acute geriatrics had a sig-
nificant higher number of comorbidities compared to
patients admitted to geriatric rehabilitation (5.0 and 4.0,
respectively, p= 0.002) and were more often cognitively
impaired (67.9% and 55.4%, respectively, p= 0.029).
Overall, male patients were more often bedridden (35.2%
and 24.0%, respectively, p= 0.038), suffered more often
from a coronary heart disease (42.9% and 29.0%, respec-
tively, p= 0.015), and demonstrated a lower level of
functionality than female patients (FIM score 70.0 points
and 78.5 points, respectively, p= 0.007), whereas females
were significantly more osteoporotic than males (32.5% and
19.0%, respectively, p= 0.013).
Prevalence of probable and confirmed sarcopenia
Results from the assessment of sarcopenia, stratified by
wards and by gender, are summarized in Table 2 and Fig. 1.
Out of 305 patients, 161 patients (52.8%; CI 47.2–58.4%)
were classified as non-sarcopenic and 75 patients (24.6%;
CI 19.8–29.4%) were classified as probable sarcopenic
according to the criteria of EWGSOP2. Sarcopenia was
diagnosed in 69 patients (22.6%; CI 17.9–27.3%), of which
60 patients (19.7%; CI 15.2–24.2%) fulfilled the criteria for
severe sarcopenia. Patients admitted to acute geriatrics had a
lower HGS than patients admitted to geriatric rehabilitation
(39.0 kPa and 40.0 kPa, respectively, p= 0.048), and pre-
valence of probable sarcopenia was higher in acute geriatric
patients (28.5% and 17.9%, respectively, p= 0.038).
Compared to women, men showed a lower prevalence of
probable sarcopenia (18.1% and 28.0%, respectively, p=
0.056) and a higher prevalence of confirmed sarcopenia
(26.7% and 20.5%, respectively, p= 0.221), even though
the differences were not found to be statistically significant.
In the 37 patients assessed in acute geriatrics as well as
geriatric rehabilitation, Cohen’s kappa coefficient of
0.778 showed substantial to high reliability for diagnosis of
confirmed sarcopenia (Supplemental Table 1).
Parameters associated with probable and confirmed
sarcopenia
Results of the multivariate regression analysis, adjusted for
age and sex, to investigate parameters for association with
probable and confirmed sarcopenia, are shown in Table 3.
Low calf circumference (OR 4.05; CI 1.78–9.21), low BMI
(OR 3.76; CI 1.59–8.88), cognitive impairment (OR 2.20;
CI 1.01–4.81) and risk of malnutrition (OR 5.68; CI
2.28–14.13) were found to be positively associated with
confirmed sarcopenia. In contrast, probable sarcopenia was
found to be positively associated solely with cognitive
impairment (OR 2.68; CI 1.36–5.28).
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Discussion
In this study, sarcopenia was diagnosed in 22.6% of ger-
iatric inpatients, and multiple parameters were found to be
independently associated with sarcopenia. To the best of the
authors’ knowledge, this is the first study to investigate the
prevalence of sarcopenia in both acute care and rehabilita-
tion settings, and to evaluate parameters associated with
probable and confirmed sarcopenia using diagnostic criteria
of EWGSOP2.
Other studies reported on prevalence of sarcopenia in
hospitalized older patients using criteria of EWGSOP2 and
found prevalence rates of 18.1, 18.9 and 22.8% [16–18].
Although these data are similar to those found in our cohort,
the participants of these three studies were younger than
ours with a median age between 65.0 and 80.7 years. Fur-
thermore, two of these studies used Dual Energy X-Ray
Absorptiometry (DEXA) [16] or computed tomography
[17] for quantification of muscle mass. However, numbers
of comorbidities of our patients were comparable to those
found in other studies [16, 18, 31]. In our cohort, baseline
characteristics as well as prevalence of sarcopenia did not
differ substantially between the two ward types, whereas
probable sarcopenia (HGS below cut-off points) was
detected significantly more often in acute geriatric patients
than in patients of geriatric rehabilitation. This finding may
be explained by the fact that patients of acute geriatrics
presented a transiently aggravated muscle weakness due to
acute illness, leading to a potential overestimation of
probable and confirmed sarcopenia in acute patients. In
contrast, patients admitted to geriatric rehabilitation might
have benefitted from medical, nutritional and physiotherapy
interventions during their preceding acute hospitalization.
This may help to explain the lower prevalence of probable
sarcopenia in patients of geriatric rehabilitation compared to
acute geriatric patients.
Associations of low calf circumference [32], malnutrition
[2] and cognitive impairment [3] with sarcopenia are well
known. A previous pilot study used the new criteria of
EWGSOP2 to analyze parameters for association with sar-
copenia and found, in contrast to our data, only low MAC to
be positively associated with the disease, although causality
cannot be established in a cross-sectional study [33].
However, the sample size of this study was small (n= 40),
and the patients were younger (mean age of 70.0 years)
compared to our cohort. Our study confirms the association
of calf circumference, low BMI, cognitive impairment and
an increased risk of malnutrition with sarcopenia according












Age, years, median (IQR) 84.0 (10.0) 84.0 (10.0) 84.0 (8.8) 84.0 (11.5) 84.0 (10.0)
BMI, kg/m2, median (IQR) 25.6 (6.6) 25.5 (6.4) 25.6 (6.1) 26.0 (5.0) 25.2 (7.2)
Calf circumference, cm, median (IQR) 32.5 (5.0) 32.0 (5.0) 33.5 (5.3) 33.0 (4.0) 32.0 (5.4)
Mid-arm circumference, cm, median (IQR) 26.5 (5.5) 26.0 (5.0) 26.5 (6.4) 27.0 (4.5) 26.0 (5.9)
Phase angle, degree, median (IQR) 4.6 (0.8) 4.6 (0.7) 4.5 (0.8) 4.7 (1.0) 4.5 (0.8)
Bedridden, n (%) 85 (27.9) 55 (28.5) 30 (26.8) 37 (35.2) 48 (24.0)a
Length of hospital stay, days, median (IQR) 16.0 (9.0) 16.0 (9.0) 21.0 (12.8)a 17.0 (12.0) 16.0 (9.0)
Comorbidities
Hypertension, n (%) 211 (69.2) 135 (69.9) 76 (67.9) 73 (69.5) 138 (69.0)
Coronary heart disease, n (%) 103 (33.8) 63 (32.6) 40 (35.7) 45 (42.9) 58 (29.0)a
Chronic kidney disease, n (%) 138 (45.2) 92 (47.7) 46 (41.1) 53 (50.5) 85 (42.5)
Diabetes, n (%) 74 (24.3) 47 (24.4) 27 (24.1) 32 (30.5) 42 (21.0)
Osteoporosis, n (%) 85 (27.9) 56 (29.0) 29 (25.9) 20 (19.0) 65 (32.5)a
Number of drugs, median (IQR) 7.0 (5.0) 7.0 (5.0) 7.0 (4.0) 7.0 (4.0) 7.0 (5.0)
Number of comorbidities, median (IQR) 5.0 (2.0) 5.0 (2.0) 4.0 (3.0)a 5.0 (2.0) 5.0 (2.0)
Geriatric assessment parameters
Cognitive Impairment (MMSE <27 points), n (%) 193 (63.3) 131 (67.9) 62 (55.4)a 70 (66.7) 123 (61.5)
At risk of malnutrition (NRS ≥3 points), n (%) 165 (54.1) 100 (51.8) 65 (58.0) 58 (55.2) 107 (53.5)
FIM score, points, median (IQR) 76.0 (28.0) 75.0 (28.5) 78.5 (26.8) 70.0 (29.0) 78.5 (26.8)a
BMI body mass index, FIM functional independence measure, IQR interquartile range, MMSE mini mental state exam, NRS nutritional risk
screening.
aSignificant group difference (p <0.05) between the groups “acute geriatrics” and “geriatric rehabilitation”, as well as “males” and “females”.
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to new criteria of EWGSOP2. We also demonstrate that all
these parameters are correlated with confirmed sarcopenia,
but not with probable sarcopenia. These findings suggest
that assessment of both HGS and muscle mass are necessary
to detect patients with low BMI and at risk for malnutrition
who could benefit from nutritional and physiotherapy
interventions. However, if assessment of muscle quantity,
e.g., by using BIA or DEXA, is not available, clinical
measures may support screening and evaluation of patients
at risk for sarcopenia. These clinical measures including
evaluation of nutritional status are easy available and part of
the comprehensive geriatric assessment, which is routinely
performed in geriatric hospitals [34].
Despite this fact, challenges in assessing geriatric inpa-
tients also must be taken into account. Using EWGSOP2
cut-off points for low physical performance, a substantial
proportion of both sarcopenic (87.0%) and non-sarcopenic
(67.1%) participants of our cohort presented a TUG ≥ 20 s at
admission. This finding is in line with other data demon-
strating that in hospitalized geriatric patients with a mean
age of 85.6 years, mean time to perform the TUG was 33.3 s
[35]. Defined in 1991, the cut-off point of 20 s for the TUG
was based on a community-dwelling population with a
mean age of 79.5 years, in which all those who completed
the TUG in <20 s were found to be independently mobile
[24]. Compared to the elderly community-dwelling popu-
lation, older hospitalized patients may have more mobility
limitations and lower muscle strength due to acute illness
[36]. Therefore, it is questionable whether the cut-off point
of <20 s is adequate to define severe sarcopenia in older
hospitalized patients. A universal definition of sarcopenia is
still subject of ongoing debates [9], and additional data are
needed to evaluate if a different cut-off point might be more
appropriate to assess physical performance in geriatric
hospitalized patients.
In this study, we were able to recruit 414 patients con-
secutively admitted to acute geriatrics and geriatric rehabi-
litation, with exclusion of only 72 patients due to exclusion
criteria. Furthermore, we demonstrated that diagnostic
measures for sarcopenia are feasible in geriatric hospital
settings. The high Cohen’s kappa coefficient between the
first and the second assessment in a subgroup of our study
cohort reflects the high reliability of our data. Finally, we
used a pneumatic hand dynamometer that is reliable and
Table 2 Prevalence of
sarcopenia, stratified by wards
(acute geriatrics and geriatric

















39.0 (19.5) 39.0 (21.0) 40.0 (18.0)a 51.0 (20.0) 34.5 (14.8)a
ASMI, kg/m2, median (IQR) 6.2 (1.4) 6.2 (1.4) 6.4 (1.5) 7.0 (1.1) 5.8 (1.1)a
Low physical performance
(TUG ≥20 s), n (%)
228 (74.8) 142 (73.6) 86 (76.8) 79 (75.2) 149 (74.5)
Prevalence of sarcopenia
No sarcopenia, n (%) 161 (52.8) 92 (47.7) 69 (61.6)a 58 (55.2) 103 (51.5)
Probable sarcopenia, n (%) 75 (24.6) 55 (28.5) 20 (17.9)a 19 (18.1) 56 (28.0)
Confirmed sarcopenia, n (%) 69 (22.6) 46 (23.8) 23 (20.5) 28 (26.7) 41 (20.5)
ASMI appendicular skeletal muscle mass index, IQR interquartile range, TUG timed up and go test.
aSignificant group difference (p <0.05) between the groups “acute geriatrics” and “geriatric rehabilitation”, as















Fig. 1 Assessment of sarcopenia in patients admitted to acute
geriatrics and geriatric rehabilitation (n= 305). Probable sarcope-
nia was defined by low handgrip strength and normal muscle mass
(n= 75; 24.6%). Sarcopenia was confirmed when both handgrip
strength and muscle mass were low (n= 69; 22.6%), and was classi-
fied as severe by additional documentation of low physical perfor-
mance (n= 60; 19.7%).
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more practical compared to a hydraulic dynamometer to
assess HGS in geriatric patients [37].
Some limitations need to be addressed. The results of this
single-centre study focusing on Caucasian geriatric inpa-
tients of a wealthy country are not generalizable. Also, as
the highest measured BMI in this study was 35.0 kg/m2, our
findings are not applicable for patients with a BMI >35 kg/
m2. Therefore, multicentre-studies based on larger sample
sizes are needed to enhance generalizability of the data. In
our study, we used BIA for the evaluation of muscle mass,
which relies on prediction equations to estimate different
body compartments [38]. In older and obese patients, BIA
potentially overestimates skeletal muscle mass compared to
DEXA [39]. In addition, BIA results can also be influenced
by changes in fluid distribution due to acute disease.
Nevertheless, BIA is a portable and validated device that is
harmless for the patient and is established for time-saving and
cost-effective assessment of muscle mass [9, 39]. Furthermore,
the geriatric baseline assessments were performed by various
assessors in clinical daily practice with a potential to unequal
application. However, assessment of HGS and muscle mass
was performed by only two investigators. Finally, parts of the
geriatric assessment included self-reported outcomes (e.g.,
NRS 2002 using self-reported weight loss or reduced food
intake), which may be imprecise in patients with cognitive
impairment. To reduce this bias, we excluded patients who
were unable to follow the study procedure due to severe
cognitive impairment, and only five (1.6%) of the included
patients had a MMSE <10 points.
Despite these limitations, our study has clinical impli-
cations. To prevent further decline in sarcopenic geriatric
patients, early diagnosis of this condition is crucial in order
to timely target specific interventions designed to build up
muscle strength and function. Therefore, in completion of
the comprehensive geriatric assessment, it will be key to
implement diagnostic measures for sarcopenia as a standard
in daily practice to identify geriatric patients at risk. As our
data demonstrate, the assessment of both muscle mass and
function are needed to identify those vulnerable patients.
Furthermore, specific treatments for sarcopenia, namely
combined early nutritional and physiotherapy interventions,
need to be further evaluated and implemented in order to
delay disease progression and to improve clinical outcomes
in sarcopenic patients.
Conclusion
Sarcopenia is highly prevalent in patients admitted to acute
geriatrics and geriatric rehabilitation, and multiple para-
meters were found to be associated with the disease. Rou-
tinely performed diagnostic measures at hospital admission
and prompt interventional approaches are needed to build
up muscle strength and function and to prevent adverse
clinical outcomes in these patients.
Acknowledgements The authors would like to thank all the partici-
pants for their valuable contribution to this study and the staff for their
friendly cooperation.
Funding DB: His work was in part supported by the “For-
schungsfonds der Geriatrischen Universitätsklinik”, Bern/Switzerland.
The funder had no role in study design, data collection and analysis,
decision to publish or preparation of the manuscript.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Table 3 Association of
parameters with probable and
confirmed sarcopenia.




OR (95% CI) P value OR (95% CI) P value
Low calf circumference (<31 cm) 1.52 (0.64–3.63) 0.348 4.05 (1.78–9.21) 0.001
Low mid-arm circumferencec 1.29 (0.61–2.73) 0.501 0.64 (0.28–1.45) 0.284
Low BMId 0.27 (0.08–0.89) 0.031 3.76 (1.59–8.88) 0.003
Cognitive impairment (MMSE <27 points) 2.68 (1.36–5.28) 0.004 2.20 (1.01–4.81) 0.048
Low physical performance (TUG ≥20 seconds) 1.44 (0.68–3.06) 0.339 2.25 (0.89–5.67) 0.086
At risk of malnutrition (NRS ≥3 points) 0.68 (0.35–1.29) 0.236 5.68 (2.28–14.13) <0.001
Functional disability (FIM per 10 points decrease) 1.17 (0.99–1.39) 0.068 0.97 (0.81–1.17) 0.770
BMI body mass index, CI confidence interval, FIM functional independence measure, MMSE mini mental
status exam, NRS nutritional risk screening, OR Odds ratio, TUG timed up and go test.
aReference group: patients with no sarcopenia.
bReference group: patients with no and probable sarcopenia.
cCut-off points for low mid-arm circumference (MAC): <26.5 cm and <24.5 cm for men and women ≥75
years old, <27.5 cm and <25.5 cm for men and women <75 years old.
dCut-off points for low BMI: <22 kg/m2 for persons ≥70 years old, <20 kg/m2 for persons <70 years old.
P values < 0.05 were considered to be statistically significant.
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